AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Tolfenamic acid is effective in reducing pain intensity and providing relief from mild to moderate pain. It is commonly used for conditions such as headache, toothache, menstrual cramps, musculoskeletal pain, and postoperative pain.
Anti-inflammatory Effects: Tolfenamic acid works by inhibiting the production of prostaglandins, which are chemicals in the body that promote inflammation, pain, and fever. By reducing inflammation, it helps alleviate symptoms such as swelling, redness, and discomfort associated with inflammatory conditions like arthritis and soft tissue injuries.
Treatment of Menstrual Disorders: Tolfenamic acid is often prescribed to manage symptoms of dysmenorrhea (menstrual pain) and other menstrual disorders. It helps relieve pelvic pain and cramping associated with menstruation, allowing for greater comfort and improved quality of life during menstrual periods.
Fever Reduction: Tolfenamic acid possesses antipyretic properties, meaning it can help lower fever by reducing elevated body temperature. It is sometimes used to manage fever associated with infections, inflammatory conditions, or other underlying causes.
Migraine Management: Tolfenamic acid has been studied for its effectiveness in the treatment of migraine headaches. It may help alleviate migraine symptoms, including headache pain, nausea, and sensitivity to light and sound, although its use for this purpose may vary depending on individual response and physician recommendation.
Dosing and Administration: Tolfenamic acid is typically available in oral dosage forms, such as tablets or capsules. The dosage and frequency of administration depend on the specific medical condition being treated, the severity of symptoms, and individual patient factors. It is usually taken with food to minimize gastrointestinal side effects.
Side Effects: Common side effects of tolfenamic acid may include gastrointestinal upset, such as abdominal pain, indigestion, nausea, vomiting, diarrhea, or constipation. Long-term use of NSAIDs like tolfenamic acid may increase the risk of gastrointestinal ulcers, bleeding, and perforation. Other potential side effects include headache, dizziness, drowsiness, rash, allergic reactions, and elevation of liver enzymes.
Contraindications: Tolfenamic acid is contraindicated in individuals with a history of hypersensitivity reactions to NSAIDs, aspirin, or other related medications. It should be used with caution in patients with a history of peptic ulcer disease, gastrointestinal bleeding, renal impairment, heart failure, hypertension, or other cardiovascular risk factors.
Drug Interactions: Tolfenamic acid may interact with other medications, including anticoagulants, antiplatelet agents, corticosteroids, selective serotonin reuptake inhibitors (SSRIs), diuretics, and certain antihypertensive drugs. It is important to consult with a healthcare professional or pharmacist before taking tolfenamic acid concurrently with other medications.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0.4 | -0.4 | |
ADHD | 6.2 | 0.4 | 14.5 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.5 | -1.5 |
Allergic Rhinitis (Hay Fever) | 2.6 | 1.9 | 0.37 |
Allergies | 4.8 | 3.7 | 0.3 |
Allergy to milk products | 1.8 | 1.1 | 0.64 |
Alopecia (Hair Loss) | 1.8 | 1.8 | |
Alzheimer's disease | 5 | 5.4 | -0.08 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.9 | 1.8 | 1.17 |
Ankylosing spondylitis | 4.3 | 2.3 | 0.87 |
Anorexia Nervosa | 0.5 | 2.3 | -3.6 |
Antiphospholipid syndrome (APS) | 1.8 | 0 | 0 |
Asthma | 1 | 2 | -1 |
Atherosclerosis | 1.5 | 2 | -0.33 |
Atrial fibrillation | 3.7 | 2.4 | 0.54 |
Autism | 11 | 9.8 | 0.12 |
Barrett esophagus cancer | 0.8 | 0.3 | 1.67 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.7 | 1.3 | 0.31 |
Brain Trauma | 0.6 | 0.6 | 0 |
Carcinoma | 3.8 | 3.1 | 0.23 |
Celiac Disease | 2.5 | 4.3 | -0.72 |
Cerebral Palsy | 2 | 1.5 | 0.33 |
Chronic Fatigue Syndrome | 7 | 6.9 | 0.01 |
Chronic Kidney Disease | 2.2 | 1.4 | 0.57 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.6 | 0.4 | 5.5 |
Chronic Urticaria (Hives) | 1.9 | 2.6 | -0.37 |
Coagulation / Micro clot triggering bacteria | 1.6 | 1.3 | 0.23 |
Colorectal Cancer | 6 | 1 | 5 |
Constipation | 1.1 | 0.6 | 0.83 |
Coronary artery disease | 1.9 | 1.2 | 0.58 |
COVID-19 | 14.2 | 15.4 | -0.08 |
Crohn's Disease | 9.9 | 6.2 | 0.6 |
cystic fibrosis | 0.7 | 1 | -0.43 |
deep vein thrombosis | 0.7 | 0.8 | -0.14 |
Depression | 13.2 | 10.2 | 0.29 |
Dermatomyositis | 0.3 | 0.4 | -0.33 |
Eczema | 1.5 | 2.6 | -0.73 |
Endometriosis | 3.3 | 1.3 | 1.54 |
Eosinophilic Esophagitis | 0.5 | 0.4 | 0.25 |
Epilepsy | 4.1 | 4.2 | -0.02 |
Fibromyalgia | 3.4 | 3.6 | -0.06 |
Functional constipation / chronic idiopathic constipation | 5.9 | 4.4 | 0.34 |
gallstone disease (gsd) | 2.5 | 1 | 1.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 1.3 | 0.62 |
Generalized anxiety disorder | 2.6 | 2.2 | 0.18 |
giant cell arteritis | 0.4 | -0.4 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 1.6 | 0.9 | 0.78 |
Halitosis | 1.3 | 0.3 | 3.33 |
Hashimoto's thyroiditis | 2 | 0.9 | 1.22 |
Hidradenitis Suppurativa | 0.8 | 0.4 | 1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.5 | 1.3 | 1.69 |
hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | 0 |
hyperglycemia | 0.2 | 3.2 | -15 |
Hyperlipidemia (High Blood Fats) | 1.1 | 0.2 | 4.5 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 3 | 5.5 | -0.83 |
Hypothyroidism | 1.3 | -1.3 | |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 5.4 | -5.4 | |
Inflammatory Bowel Disease | 5.5 | 9.6 | -0.75 |
Insomnia | 1.3 | 0.6 | 1.17 |
Intelligence | 1.7 | 0.7 | 1.43 |
Intracranial aneurysms | 1.9 | 0.2 | 8.5 |
Irritable Bowel Syndrome | 5.8 | 5.1 | 0.14 |
Liver Cirrhosis | 5.6 | 3.3 | 0.7 |
Long COVID | 10.4 | 9.2 | 0.13 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 1.2 | 1.8 | -0.5 |
ME/CFS with IBS | 1.7 | 2.5 | -0.47 |
ME/CFS without IBS | 2.1 | 2 | 0.05 |
Menopause | 2.5 | 2.5 | |
Metabolic Syndrome | 9.4 | 10.1 | -0.07 |
Mood Disorders | 16.6 | 10.3 | 0.61 |
multiple chemical sensitivity [MCS] | 1.6 | 0.5 | 2.2 |
Multiple Sclerosis | 6.3 | 6.6 | -0.05 |
Multiple system atrophy (MSA) | 2.5 | 1.3 | 0.92 |
Neuropathy (all types) | 1.3 | 0.2 | 5.5 |
neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 6.7 | -1.68 |
NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
Obesity | 8.2 | 6.4 | 0.28 |
obsessive-compulsive disorder | 8.5 | 5.1 | 0.67 |
Osteoarthritis | 3.2 | 0.4 | 7 |
Osteoporosis | 2 | 1.9 | 0.05 |
pancreatic cancer | 0.8 | 0.8 | |
Parkinson's Disease | 3.7 | 4.1 | -0.11 |
Polycystic ovary syndrome | 2.9 | 2.7 | 0.07 |
Postural orthostatic tachycardia syndrome | 0.4 | 0.7 | -0.75 |
Premenstrual dysphoric disorder | 1.1 | 0.5 | 1.2 |
primary biliary cholangitis | 0 | 1.2 | 0 |
Psoriasis | 4.9 | 4 | 0.23 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.2 | 4.4 | 0.64 |
Rosacea | 0.8 | 0.6 | 0.33 |
Schizophrenia | 8.4 | 2.1 | 3 |
scoliosis | 0.3 | 0.5 | -0.67 |
Sjögren syndrome | 3.9 | 4.2 | -0.08 |
Sleep Apnea | 2 | 1.5 | 0.33 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.6 | 1.17 |
Stress / posttraumatic stress disorder | 3.4 | 2.7 | 0.26 |
Systemic Lupus Erythematosus | 5.7 | 1.9 | 2 |
Tic Disorder | 1.2 | 1.4 | -0.17 |
Tourette syndrome | 0.5 | 0.5 | 0 |
Type 1 Diabetes | 4.6 | 2.1 | 1.19 |
Type 2 Diabetes | 9.3 | 9.3 | 0 |
Ulcerative colitis | 3.3 | 7.1 | -1.15 |
Unhealthy Ageing | 7.1 | 2.5 | 1.84 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.